Probiotic-assisted colon-specific delivery of diclofenac sodium from guar gum matrix tablets: In vitro evaluation

Prashant Kumar Ghosh, Vipin Bihari Gupta, Bhavik Gondoliya, Mahendra Singh Rathore

Abstract


Purpose: The aim of present work was to investigate the in vitro release profile of diclofenac sodium from matrix tablets,which were prepared using guar gum with and without probiotics. Methods: Six matrix tablets formulations (F1-F6) of
diclofenac sodium containing varying proportions of guar gum, 10-60% of tablet weight were prepared by wet granulation method and evaluated in vitro for their release profile. Four matrix tablets formulations (F7-F10) of diclofenac with guar
gum (40%) were prepared incorporating varying concentration of commercial spores of lactobacillus and bifidobacterium species that are commonly found in colon microflora. Results: The tablets having same concentration of guar gum without probiotics (F4) showed a 54.47% cumulative release of diclofenac after 24 hr while that in presence of probiotics (F9) was 73.01%. These drug release studies were conducted without rat caecal content. In another set of experiments, the drug release studies were carried out in presence of rat caecal content. In such experiments, more than 95% drug was released from F4 and F9 formulations after 24 hr. Conclusion:The results showed that commercial probiotics are capable in digesting guar gum. These probiotics may be used to assist in colon delivery of drugs from formulations prepared with guar gum.


Full Text:

PDF

References


Friend DR. New oral delivery systems for treatment of inflammatory

bowel disease. Adv Drug Del Rev 2005;57:247-65.

Sinha VR, Mittal BR, Bhutani KK, Kumria R. Colonic drug delivery of

-fluorouracil: An in vitro evaluation. Int J Pharm 2004;269:101-8.

Watts P, Illum L. Colonic drug delivery. Drug Dev Ind Pharm 1997;23:893-913.

Fatima LAA, Chandran S. Multiparticulate formulation approach to

colon specific drug delivery: Current perspectives. J Pharm Pharmaceut

Sci 2006;3:327-38.

Libo Y, James SC, Joseph AF. Colon-specific drug delivery: New

approaches and in vitro/in vivo evaluation. Int J Pharm 2002;235:1-15.

Vandamme TF, Lenourry A, Charrueau C, Chaumeil JC. The use of

polysaccharides to target drugs to the colon. Carbohydrate Polymers

;48:219-31.

Ishibashi T, Hatano H, Kobayashi M, Mizobe M, Yoshino H. In vivo drug

release behaviour in dogs from a new colon-targeted delivery system.

J Control Release 1999;57:45-53.

Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted

drug delivery systems. J Pharm Pharmaceut Sci 2003;6:33-66.

Jain NK. Advances in controlled and novel drug delivery. 1st ed. New

Delhi: CBS Publishers and Distributors; 2001.

Wilson PJ, Basit AW. Exploiting gastrointestinal bacteria to target drugs

to the colon: An in vitro study using amylose coated tablets. Int J of

Pharm 2005;300:89-94.

Rubinstein A. Microbially controlled drug delivery to the colon. Bioph

Drug Dispos 1990;11:465-75.

Sinha VR, Mittal BR, Kumria R. In vivo evaluation of time and site of

disintegration of polysaccharide tablet prepared for colon-specific drug

delivery. Int J Pharm 2005;289:79-85.

Rubinstein A, Radai R, Ezra M, Pathak S, Rokem S. In vitro evaluation

of calcium pectinate: A potential colon-specific drug delivery carrier.

Pharm Res 1993;10:258-63.

Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery.

Int J Pharm 2001;241:19-38.

Tuohy KM, Kolid S, Lustenberger AM, Gibson GR. The prebiotic effects

of biscuits containing partially hydrolysed guar gum and fructo-

oligosaccharides – a human volunteer study. Br J Nutr 2001;86:341-8.

Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS.

Bifidobacterium longum, a lactic acid-producing intestinal bacterium

inhibits colon cancer and modulates the intermediate biomarkers of

colon carcinogenesis. Carcinogenesis 1997;18:833-41.

Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory

drugs and colorectal cancer. Cancer (Phila) 1994;74:1847-54.

Stürmer T, Buring J, Lee I, Kurth T, Gaziano J, Glynn R. Colorectal

Cancer After Start of Nonsteroidal Anti-Inflammatory Drug Use. Am J

Med 2006;119:494-502.

Hixson LJ, Alberts DS, Krutzsch M, Einsphar J, Brendel K, Gross PH,

et al. Antiproliferative effect of nonsteroidal anti-inflammatory drugs

against human colon cancer cells. Cancer Epidemiol Biomarkers Prev

;3:433-8.

Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, Willis

D, et al. The inhibition of colon-26 adenocarcinoma development and

angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res

;57:1625-9.

Falkowski M, Skogstad S, Shahzidi S, Smedsröd B, Sveinbjörnsson B.

The effect of cyclooxygenase inhibitor diclofenac on experimental

murine colon carcinoma. Anticancer Res 2003;23:2303-8.

Bjorkman R, Ullman A, Hedner J. Morphine–sparing effect of Diclofenac

in cancer pain. Eur J Clin Pharmacol 1993;44:1-5.

Krishnaiah YS, Satyanarayana S, Rama Prasad YV, Narasimha SR.

Evaluation of guar gum as a compression coat for drug targeting to

colon. Int J Pharm 1998;171:137-46.

Tomlin J, Read NW, Edwards CA, Duerden BI. The degradation of guar

gum by a faecal incubation system. Br J Nutr 1986;55:481-6.

Tomlin J, Read NW. The relation between bacterial degradation of

viscous polysaccharides and stool output in human beings. Br J Nutr

l988;60:461-75.




DOI: http://dx.doi.org/10.22377/ajp.v4i4.225

Refbacks

  • There are currently no refbacks.